# Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

> **NCT03436862** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 37 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03436862
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-23
- **Primary completion:** 2022-05-05
- **Final completion:** 2023-04-04
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03436862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03436862, "Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03436862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*